Jean‐Christophe Ianotto

Author

Centre Hospitalier Régional Universitaire de Brest ORCID

Also Known As

IANOTTO, Jean-Christophe, Ianotto JC, Ianotto Jean-Christophe, Ianotto, J C, Ianotto, Jean-Christiophe, Ianotto, Jean-Christophe, J C Ianotto, J Ianotto, J-C Ianotto, J-C. Ianotto

274

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Régional Universitaire de Brest Inserm Centre Hospitalier Universitaire d'Angers Hôpital Saint-Louis Centre Hospitalier Régional et Universitaire de Nancy

About

Jean‐Christophe Ianotto is an author at Centre Hospitalier Régional Universitaire de Brest specializing in medicine, hematology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	24	1.1K
2	Health Sciences	5	5	117
3	Cell Biology	5	5	119
4	Public Health	3	3	66
5	Biomedical Engineering	1	1	14

Jean‐Christophe Ianotto

Publications

3.4K

Citations

H-Index

Page 1

	Year	Citations
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia Gabriel Étienne, Joëlle Guilhot, Delphine Réa, Journal of Clinical Oncology Hematological MalignancyStop ImatinibChronic Myeloid LeukemiaPurpose ImatinibMedicine	2016	484
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs Robyn M. Emanuel, Amylou C. Dueck, Holly L. Geyer, Journal of Clinical Oncology	2012	441
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study Delphine Réa, Franck E. Nicolini, Michel Tulliez, Blood	2016	314
Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients Xénia Cabagnols, Fabrizia Favale, Florence Pasquier, Blood	2015	182
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations Emmanuelle Verger, Bruno Cassinat, Aurélie Chauveau, Blood	2015	154
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study Delphine Réa, Guylaine Henry, Zena Khaznadar, Haematologica	2017	147
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients Franck E. Nicolini, Stéphanie Dulucq, Lisa Boureau, Clinical Cancer Research	2019	108
Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia Laurence Legros, Franck E. Nicolini, Gabriel Étienne, Cancer	2017	105
Simulated patient and role play methodologies for communication skills and empathy training of undergraduate medical students Cristina Bagacean, Ianis Cousin, A Ubertini, BMC Medical Education	2020	95
Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study Lénaïg Le Clech, Jean‐Philippe Talarmin, Marie‐Anne Couturier, Infectious Diseases	2018	84

Page 1